Hangzhou Rongli Pharmaceutical Technology

Hangzhou Rongli Pharmaceutical Technology is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence metabolic and chronic diseases, including type 2 diabetes, non-alcoholic steatohepatitis (NASH), and chronic cough. Its lead programs include RL-007, a GPR119 agonist for diabetes, and RL-010, a selective THR-beta agonist for NASH. By leveraging its internal R&D capabilities, Hangzhou Rongli aims to provide effective and safe treatment options for patients with significant unmet medical needs. The company is led by a team of experienced scientists with extensive backgrounds in global drug development.